11 citations
,
March 2014 in “Journal of Investigative Dermatology” Genetic mutation and carcinogen treatment are both needed for skin cancer to develop in these specific mice.
12 citations
,
November 2007 in “Journal of Investigative Dermatology” CD200 is not a reliable marker for identifying stem cells in all skin types.
4 citations
,
June 2025 in “Cell Reports” Clonally expanded CD8+ T cells cause alopecia areata.
7 citations
,
October 2024 in “Frontiers in Immunology” A humanized CXCL12 antibody may delay and treat alopecia areata by altering the immune response.
November 2025 in “Journal of Investigative Dermatology” PCFCL may have unrecognized subtypes and needs more research.
5 citations
,
January 2021 in “iScience” Using a combination of specific cell cycle regulators is better for safely keeping hair root cells alive indefinitely compared to cancer-related methods.
6 citations
,
November 2018 in “American journal of transplantation” UV light helped human hair transplants survive in mice without broad immunosuppression.
1 citations
,
April 2019 in “The journal of investigative dermatology/Journal of investigative dermatology” Melanocyte-associated antigens may play a key role in alopecia areata and could be targets for new treatments.
January 2024 in “Wiadomości Lekarskie” DEC cells show promise as a safe and effective treatment for Duchenne muscular dystrophy.
8 citations
,
August 2025 in “Journal of Translational Medicine” CD44 signaling can help heal wounds without scars.
1 citations
,
July 2025 in “Scientific Reports” CD133+ cells are crucial for hair growth.
2 citations
,
June 2025 in “Journal of Investigative Dermatology” CD8+ T cells re-expressing CD45RA may predict treatment resistance in severe alopecia areata.
6 citations
,
September 2013 in “Journal of Evolution of Medical and Dental Sciences” Low CD4 counts in HIV patients are linked to more skin disorders.
January 2025 in “Cell Communication and Signaling” CXXC5 can both suppress and promote cancer, making it a complex target for treatment.
245 citations
,
April 2009 in “Circulation Research” CD133+ cells help heal diabetic ulcers by promoting blood vessel growth and activating Wnt signaling.
23 citations
,
January 2024 in “Nature Immunology” γδ T cells adapt uniquely to different tissues in mice.
12 citations
,
April 2017 in “Experimental and Therapeutic Medicine” Patients with severe active alopecia areata have lower CD200 expression and an imbalance in their immune system.
January 2019 in “11th World congress for hair research” April 2023 in “Journal of Investigative Dermatology” IL-17 plays a key role in severe hair loss in chronic alopecia areata.
11 citations
,
September 2019 in “The journal of investigative dermatology/Journal of investigative dermatology” A specific group of skin stem cells was found to help maintain hair follicle cells.
2 citations
,
September 2024 in “PLoS ONE” Bendamustine combined with tucidinostat may effectively treat adult T-cell leukemia.
11 citations
,
February 2022 in “Scientific Reports” CD26+ fibroblasts improve skin healing and integration better than CD26− fibroblasts.
16 citations
,
April 2024 in “Proceedings of the National Academy of Sciences” HDAC4 and HDAC7 are crucial for Th17 cell development and could be targeted to treat inflammatory diseases.
16 citations
,
November 2005 in “Journal of Clinical Pathology” CD1d expression in scalp skin and hair follicles changes with the hair cycle and may help protect against microbes.
41 citations
,
April 2019 in “PLOS genetics” CD34+ and CD34- melanocyte stem cells have different regenerative abilities.
September 2017 in “The journal of investigative dermatology/Journal of investigative dermatology” Blocking CCR5 can prevent and improve hair loss in alopecia areata.
April 2016 in “The journal of investigative dermatology/Journal of investigative dermatology” Combining UVB irradiation and anti-CD154 antibody improves hair follicle transplant survival.
4 citations
,
October 2018 in “Asia-Pacific Journal of Clinical Oncology” CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.
60 citations
,
October 2020 in “Nature Communications” AP-1 and TGFß work together to drive resistance in basal cell carcinoma, suggesting new treatment options.
1 citations
,
May 2025 in “Frontiers in Medicine” Dual-targeted therapy is effective and safe for difficult-to-treat inflammatory bowel disease.